MicroRNA-935 Directly Targets FZD6 to Inhibit the Proliferation of Human Glioblastoma and Correlate to Glioma Malignancy and Prognosis

Dainan Zhang¹,², Shunchang Ma², Chuancuo Zhang¹,², Peiliang Li¹,⁴, Beibei Mao¹,⁵, Xiudong Guan¹,², Wenjianlong Zhou¹, Jiayi Peng¹, Xi Wang¹, Shaomin Li⁶ and Wang Jia¹,²*

¹ Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, ² Beijing Neurosurgical Institute, Capital Medical University, Beijing, China, ³ Chinese Glioma Genome Atlas Network (CGGA), Beijing, China, ⁴ Department of Neurosurgery, Ditan Hospital, Capital Medical University, Beijing, China, ⁵ Department of Neurosurgery, Shijitan Hospital, Capital Medical University, Beijing, China, ⁶ Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, United States

MicroRNAs (miRNAs) are involved in human glioblastoma (GB). MiR-935 has been reported to have both tumor-inhibiting and tumorigenesis effects, but its role in GB remains unclear. Because of the high mortality and morbidity associated with the malignancy of GB, a deeper understanding of the molecular crosstalk that occurs in GB is needed to identify new potential targets for treatment. At present, the mechanism of GB at the molecular level is not fully understood. With the aid of bioinformatic analysis, miR-935 was significantly downregulated in GB, and it presented a poorer outcome. In the glioma cell line and in the nude mice model, the miR-935 inhibited cell proliferation by modulating cell circles in vitro and in vivo. Then, the target genes of miR-935 were analyzed by using the online database, and the direct binding was tested with a luciferase analysis. FZD6 was found to be the direct target of miR-935. The effect of miR-935 was recovered by the overexpression of FZD6 in vitro. In addition, the negative correlation of miR-935 and the expression of FZD6 were confirmed in our clinical samples, and the expression of FZD6 has a strong correlation with tumor malignancy and prognosis. This study showed that miR-935 directly inhibited the expression of FZD6 and inhibited the cell proliferation, thereby suppressing the development of GB, suggesting that miR-935 is a cancer suppressor miRNA and may become a prognostic biomarker or a promising potential therapeutic target for human GBs.

Keywords: GB, cell proliferation, clinical prognosis, FZD6, MiR-935

INTRODUCTION

Glioblastoma (GB) is the most common intracranial invasive glioma (1). The usage of a comprehensive treatment significantly improved the prognosis of all patients with glioma. However, the nature of high proliferative capacity, invasive growth behavior, and tumor recurrence impose a poor prospect for survival in patients with GB (2). The current treatment
includes surgery, radiology therapy, and chemotherapy drugs, such as temozolomide. The failure of conventional therapeutic interventions was believed to be related to rapid proliferation and cellular heterogeneity of GB cells (3, 4). In this case, the development of new therapeutic targets to inhibit the tumor proliferation and of the molecular biomarkers that can predict clinical outcomes in patients with GB seems to be urgent, which will help comprehend their tumor progression and supply personalized treatment.

MicroRNAs (miRNAs) are a group of single-strand, small non-coding RNAs that induce mRNA degradation via sequence-specific binding to the 3’ UTR region of the target mRNAs (5, 6). In this way, miRNAs repress the expression of a wide range of genes and take part in posttranscriptional regulation in a variety of cellular cancer behaviors, such as proliferation, apoptosis, invasion, and migration (7). It has been reported that miRNAs regulate the progression of GB by targeting tumor-suppressor genes or oncogenes (8–11). Furthermore, miRNAs have been shown to act as diagnostic and prognostic biomarkers of disease subtypes and outcomes (12, 13).

MiR-935 was identified as a modulator in several types of cancers. On the one hand, miR-935 was reported to depress the expression of IREB2 and enhance the invasion of cells in the renal cancer cell model (14) or promote cell proliferation, migration, and invasion in colorectal cancer (15), pancreatic cancer (16), and liver cancer (17). On the other hand, miR-935 was reported to be a tumor suppressor in osteosarcoma (18). However, to the best of our knowledge, no study concerning how miR-935 affects the development and progression of GB has been performed and the mechanism remains to be elucidated.

In the present study, we compared the expression of miR-935 in human GB tumor tissues and adjacent normal tissues using a gene expression omnibus (GEO) dataset and plotted the differential expression-related overall survival in the Chinese Glioma Genome Atlas (CGGA) dataset. Then, the effect of miR-935 on glioma cell proliferation and cell cycle modulation was tested in vitro and in vivo. Additionally, dual-luciferase assays and rescue experiments were conducted to show that miR-935 mediated the regulation of GB progression by directly binding miR-935 to FZD6. The present study affirmed the effects of miR-935 on human GB, and it is likely that the miR-935/FZD6 axis may act as a prognosis predictor and a potential molecular therapeutic target for GB.

MATERIALS AND METHODS

Bioinformatic and Statistical Analyses

The data for miRNA expressions and clinical phenotypes and the outcomes of GB were retrieved from the gene expression omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) and from the Chinese Glioma Genome Atlas (CGGA) (http://www.cgga.org.cn/). The gene expression with RNA sequencing (RNAseq) datasets of The Cancer Genome Atlas (TCGA) was derived from the gene array expression profile data, GSE25631 (19, 20), which contained 82 GB (WHO IV grade) tissues and five normal brain tissues. The data from the differential expression analysis of RNA-Seq V2 was analyzed by the “DESeq2” package and plotted by the “ggplot2” package; the data presenting clinical outcomes were analyzed by packages such as “survival,” “survminer,” “ggpubr,” and “gridExtra.” All packages were run in the R environment (version 3.5.1).

Cell Lines and Cell Culture

The U87 and SHG44 cell lines used in this study were purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA). The cells were cultured in Dulbecco’s modified eagle medium (DMEM) (HyClone, SH30243.01, UT, USA), along with penicillin G (100 U/ml, Corning, NY, USA), streptomycin (100 µg/ml, Corning, NY, USA), and 10% fetal bovine serum (FBS) (Gibco, 16000-044, USA). The cells were incubated in an incubator (Thermo, Waltham, MA, USA) at 37°C in a humidified atmosphere of 5% CO₂ and 95% air. Primary cell lines were derived from patients with GB who underwent surgery at Beijing Tiantan Hospital according to a protocol reported by Dong et al. (21, 22). Patients provided informed consent as approved by the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University (KY 2018-052-01). In brief, tumor tissues were washed immediately after resection in 4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid (HEPES)-buffered saline and homogenized and treated for 30 min with 0.025% Trypsin-EDTA solution at 37°C. The cell homogenate was filtered by an 80 mm cell strainer and centrifuged at 180 g for 5 min. After two washes with medium (DMEM, 10% fetal calf serum (FCS)), the cells were seeded out for propagation and kept under differentiating conditions.

GB Sample Collection

The samples of GB, which were used for the expression level assay and were collected from patients who underwent surgery at Beijing Tiantan Hospital, were immediately frozen in liquid nitrogen after tumor resection. All patients provided written consent for the biomedical usage.

The Quantitative PCR (q-PCR) Analysis

The total cellular RNA of tissues was isolated by using a TRIzol reagent (Invitrogen, 1596-026, USA), which was dissolved in RNA-free H₂O and stored at −80°C until tested. The cDNA was generated from 1 µg RNA of each sample using RevertAid First Strand cDNA Synthesis Kit (#K1622, Thermo Scientific™, MA, USA). The protocol of real-time PCR was designed as followed: pre-denaturation at 95°C for 10 min followed by 40 cycles of denaturation at 95°C for 15 s, annealing at 60°C for 45 s, and elongation at 60°C for 1 min. The primers used in the real-time q-PCR are shown as follows: miR-935, forward: 5’-CGCTACCGCCGCCGCT-3’; reverse: 5’-AGTGCAGGGTCCGAGGATT-3’; the relative expression level of miR-935 was calculated by using the 2⁻ΔΔCt method, with U6 snRNA as the reference gene.

Cell Transfection

The miR-935 mimics and inhibitors, as well as the negative controls (NCs), were purchased from GenePharma Co., Ltd (Shanghai, China). The mimics were transfected into U87, while the inhibitors were transfected into
SHG44. The sequence of miR-935 mimics was 5'-CCAGUACCGC UUCCGUAACGGCUACUGG-3' and 5'-GGGUAGCGGAAGCGGUAACUGG-3' for inhibitors, while, for NCs, it was 5'-UUCCGGAACGUACACGUTT-3'. These miR-935 mimics/inhibitors were transfected into cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, U.S.A.), when the cell density reached 70–80%. At 48 h after transfection, the cells were collected for further analysis.

Western Blot Assay

Western blotting was performed in tissue samples with a RIPA Lysis Buffer kit (BYL40825, JRDUN Biotech, Shanghai, China) and the protein concentrations were quantified using BCA protein assay kit (PICP123223, Thermo Fischer Scientific, MA, USA). Approximately 50 μg of protein extracts were separated with 10 or 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene fluoride (PVDF) membrane. Then, the membranes were incubated with primary antibodies, such as anti-FZD6 (1:500, cat. ab98933; Abcam), anti-β-catenin (1:1000, cat. ab16051; Abcam), anti-cyclin D1 (1:200, cat. ab16663; Abcam), anti-c-myc (1:1000, cat. ab32027, Abcam), anti-PCNA (1:1000, cat. ab92552, Abcam), or anti-GAPDH (1:2000, cat. 5174; CST), overnight at 4°C. After three washes with the TBST buffer, the goat anti-mouse/rabbit secondary antibody (1:1000, cat. A0208 &A0216; Beyotime Biotechnology, Shanghai, China) was subsequently used at room temperature for 1 h, followed by another three washes with the TBST buffer. Protein bands were visualized using the Tanon 5200CE Chemi-Image System (Tanon Science and Technology Co., Ltd., Shanghai, China) and analyzed using BioImaging Systems (UVP Inc., Upland, CA). The targeted proteins were semi-quantitatively determined with the ImageJ software and were normalized to the quantified signal intensity of GAPDH.

Cell Proliferation Assay

The cell proliferation rate of U87 and SHG44 after transfection by miR-935 mimics/inhibitors was examined by the cell counting kit8 (CCK8) (Beyotime, Shanghai, China). After transfection, the U87 and SHG44 cells in the logarithmic growth phase of each transfection group were seeded in a 96-well plate at a density of 3 × 10⁴ cells per well (100 μl in each well); three wells were assigned to each experimental treatment and then cultured in a CO₂ incubator. At 0, 12, 24, 48, and 72 h after transfection, the cells were treated with CCK8 and incubated for 1 h at 37°C. Absorbance was detected at 450 nm using a microplate reader (DNM-9602, Perlong Medical Equipment Co., Ltd., Beijing) and a proliferation curve was plotted.

Cell Cycle Analysis

Cell suspensions were collected at a density of ≥3 × 10⁵ and centrifuged at 1,000 × g for 5 min, the supernatant was discarded, and the cells were washed and resuspended in 1 ml cold PBS. Cells were then fixed with 70% ethyl alcohol at 4°C overnight; the cell suspension was added into 50 μg/ml propidium iodide (7 Sea biotech, Shanghai, China) staining solution and incubated for 10 min at 37°C in the dark. The analysis of flow cytometry was performed on the BD FACSCalibur flow cytometer (Accuri C6, BD Biosciences, San Jose, CA, USA). The absorbance was detected at 488 nm and the percentage of cells in the G0/G1, S, and G2/M phases was determined using the Flowjo software (Version 10, Tree Star, Ashland, OR, USA).

Tumorigenicity in Xenografts of the Nude Mouse Model

Twelve 4–6-week-old male Balb/c nude mice, weighing 18–20 g, purchased from SLAC Laboratory Animal Co., Ltd. (Shanghai, China) were bred in a specific pathogen-free (SPF) grade laboratory in Fudan University in a 12/12 h light/dark cycle environment, with ad libitum access to food and water. All experiments involving animals were performed in accordance with the guidelines approved by the Laboratory Animal Ethics Committee of Capital Medical University, Beijing. The mice were randomly divided into two groups of six and were subcutaneously injected at unilateral submaxillary with viable U87 cells transfected with either miR-935 or miR-NC (5 × 10⁶ cells/injection) to induce primary tumors. Tumor length and width were measured every 3–4 days until the experiment was ended. Five weeks after implantation, the mice were euthanized, and the tumors were surgically dissected and weighed. The tumor volume was measured and calculated according to the formula: volume (m³) = length × width². Then, the expression of the related biomarkers was assessed by the Western blotting technique.

Luciferase Reporter Assay

With the information from the online bioinformatics website, TargetScan (http://www.targetscan.org/vert_72/) was applied in order to predict the binding sites of miR-935 and FZD6. To construct the luciferase plasmid, the 3’-UTR sequence of FZD6 or a mutant sequence was inserted into the pGL3 promoter vector (Invitrogen), which was defined as FZD6 wild type (WT) and as FZD6 mutant. The constructed report vectors containing wild-type fragments or mutant-type fragments, together with a Renilla vector and miR-935 mimics or miR-NCs, were cotransfected into U87 cells (5 × 10⁵ /well) using the Lipofectamine TM 2000 (Invitrogen) reagent. At 48 h after transfection, luciferase and Renilla signals were measured using the Dual-Glo Luciferase Assay System (E1910, Promega corporation, WI, USA), in which the firefly luciferase activity was normalized to Renilla luciferase activity.

Plasmid Constructs and Lentivirus Package

The mature sequence of human hsa-miR-935 (5’-CCAGTTACCGCTCGCCGCTAACC-3’) was annealed and inserted into the EcoRI/BamHI sites of the pLVX-ZsGreen-miRNA-Puro vector (AsiaVector Biotechnology, Shanghai, China). Virus packaging was performed in HEK 293T cells after the co-transfection of 0.5 mg pLVX-ZsGreen-miRNA-Puro (NC-GFP) vector or pLVX-ZsGreen-miRNA-Puro-hsa-miR-935 (miRNA395-GFP) vector with 1.5 mg of mixture packaging plasmids containing pHelper 1.0 vector and envelope plasmid pHelper 2.0 vector using the Lipofectamine 2000 (Life
Technologies, Carlsbad, CA, USA). Viruses were harvested 48–72 h after transfection and viral titer were then determined.

Establishment of Stable Cell Line-U87

For lentivirus transduction, 70% of confluent human glioma (U87) cells were used. Then, cells were incubated with a 1:1 precipitated mixture of lentiviral supernatants of NC-GFP or miRNA395-GFP cells and RPMI 1640 (9161, FUJIFILM Irvine Scientific, CA, USA) containing 10% FBS (HyClone Laboratories, Inc. PA, USA) for 72 h. Later, the cells were subjected into a selective medium, which contained 1 µg/ml of puromycin for 2 weeks. The establishment of hsa-miR-935-overexpressing cells was confirmed by qRT-PCR.

Brain Orthotopic Xenografts

BALB/c nude mice were anesthetized with 10% chloral hydrate (0.1 ml/10 g body weight). After fixing the mice in a prone position, an incision measuring 1.5 cm was made directly down the midline of the scalp. The scalp was retracted and the skull was exposed. Using a high-speed air-turbine drill (a burr tip size of 0.5 mm in diameter), a craniotomy was made over the right parietal bone. Five µl of a suspension containing 1 × 106 U87-GFP cells (expressing miRNA-935 or mimics NC) was injected stereotactically into the mouse brain using a 10 µl Hamilton syringe. Cells were injected in the middle of the craniotomy open window to a depth of 2.5 mm. The incision was then closed with a 6-0 surgical suture (ETHICON, Inc., Somerville, New Jersey, United States) after the bone flap was placed back and sealed with a bone wax. All mice were kept in an oxygenated warmed chamber until they were recovered from anesthesia. Tumors were monitored and quantified using an in vivo imaging system (IVIS Lumina XR, PerkinElmer, USA) after 3 weeks.

Statistical Analysis

All data were expressed as the mean ± SD. Survival curves were estimated by the Kaplan–Meier method. The Log-rank test was used to estimate the statistical differences between the survival curves. The comparison between the two groups was analyzed by the Student's t-test. The comparisons, among multiple groups, were made with a one-way ANOVA followed by the Bonferroni’s test, where p < 0.05 was considered to represent the statistical significance.

RESULTS

The miR-935 Is Downregulated in GB Tissues and Correlated With a Poorer Prognosis

We first compared the miR-935 expression level between GB and the normal brain tissues from the GSE25631 dataset. Results showed that the miR-935 expression in GB was significantly lower than that in the normal brain tissue (p < 0.05, Figure 1A). We also explored the miR-935 expression level of WHO II/III/IV grade gliomas, respectively, in the dataset microRNA_array_198 of the CGGA database; the miR-935 expression was significantly lower in the IV grade glioma than that was in the II grade and III grade gliomas (p < 0.05, Figure 1B). The Kaplan–Meier analysis showed that the lower half of the miR-935 expression was linked markedly to a shorter overall survival probability in the WHO grade IV primary glioma (p = 0.022, n = 81, Figure 1D) and even in the primary gliomas of all grades (p = 0.021, n = 172, Figure 1C). These data indicate that the expression of miR-935 is downregulated in GB tissues and that the lower expression of miR-935 may be related to a higher pathology grade and a poor prognosis.

The Transfection Efficiency of miR-935 Mimics and Inhibitors in the Established Glioma Cell Lines

We first assessed the expression levels of miR-935 in four commercially available, established human glioma cell lines (U251, U87, SHG44, and T98G), with the HEB cell as a control group. The miR-935 expression levels were the lowest in U87 and the highest in SHG44 among the four glioma cell lines (‘p < 0.05 when compared to the expression in HEB cell line, Figure 2A). We then transfected the miR-935 mimic into U87 cell lines and the inhibitor in the SHG44 cell lines. The expression of miR-935 was significantly upregulated in the miR-935 mimic transfected cells, whereas it was significantly decreased in the miR-935 inhibitor transfected cells (*p < 0.05, when compared to that in the medium, treated cells and the NC treated cells, Figure 2B).

Effect of miR-935 on Cell Proliferation and Cell Cycle in Human Glioma Cell Lines

We first investigated the effect of miR-935 on cell proliferation by transfecting miR-935 mimics in U87 cells and inhibitors in SHG44 cells. The results of the CCK8 assay indicated that the overexpression of miR-935 significantly suppressed the proliferation of U87 cells from 12 to 72 h after transfection (**p < 0.05, Figure 2C) and the downregulation of miR-935 with the inhibitor promoted the cell proliferation in SHG44 cells at 48 and 72 h (**p < 0.05, Figure 2D), respectively. Furthermore, we examined the protein expression level of proliferation-related biomarkers, β-catenin, cyclin D1, c-myc, PCNA of the miR-935 mimic-treated U87 cells, and miR-935 inhibitor-treated SHG44 cells. We found that the biomarkers were significantly downregulated by the miR-935 mimic and were significantly upregulated by the miR-935 inhibitor (**p < 0.05 when compared to the respective NC cells, Figures 2E,F). Taken together, these results demonstrate that the lower expression of miR-935 is related to enhanced cell proliferation in the human glioma cells.

We then determined the cell-cycle distribution by the analysis of flow cytometry in U87 cells after miR-935 mimics and SHG44 cells after miR-935 inhibitor were transfected. Subsequently, the portion of cells in the G0/G1 phase was significantly increased when miR-935 was enhanced, while the portions of the S phase and the G2/M phase were significantly decreased when compared to the NC-treated cells (**p < 0.05, Figure 2G). Meanwhile, in the miR-935 inhibitor-treated SHG44 cells, the portion of cells in the G0/G1 phase was significantly decreased, while the portion of S phase was significantly increased when compared to the NC-treated cells (**p < 0.05, Figure 2H). These data indicate
that the lower expression of miR-935 may enhance the cell proliferation by raising the propagation of cells in the S phase and reducing the propagation of cells in the G0/G1 phase in human glioma cells.

Overexpression of miR-935 Suppresses the Tumorigenicity of U87 Cells *in vivo*

To further confirm the activity of miR-935 in human glioma, we used the *in vivo* model of Balb/c nude mice xenograft tumor implantation. Our data showed that the transfection of miR-935 mimics significantly suppressed the tumor growth by tumor weights at the end of the experiment (*p* < 0.05 when compared with the miR-NC group, Figure 3D) and by the tumor volume measurement from 15 to 33 days after tumor implantation (Figures 3A–C) (*p* < 0.05 when compared with the miR-NC group, Figure 3E). The Western blotting analysis of proliferation of the expression of biomarkers in tumor tissues showed that the miR-935 mimic treatment suppressed the β-catenin, cyclin-D1, c-myc, and PCNA (*p* < 0.05 when compared with the miR-NC group, Figures 4G,H). Therefore, the human glioma U87 cell growth is inhibited by enhancing the expression of miR-935.

MicroRNA-935 Negatively Regulated FZD6 Expression by Binding to the 3'UTR of FZD6

The targeting relationship between miR-935 and FZD6 was predicted by searching TargetScan, a bioinformatics website (Version 7.2, http://www.targetscan.org/vert_72/) (23), and determined by the Luciferase reporter assay. We constructed two reporter vectors consisting of the luciferase coding sequence with either 3'-UTR of FZD6 (FZD6 3'UTR WT) or mutant FZD6 3'-UTR (FZD6 3'-UTR mutant) (Figure 4A). The Luciferase reporter assay revealed that the luciferase signal of the miR-935 mimic group was significantly lower than that of the NC group when transfected with the FZD6 3'-UTR WT group; however, no significant difference was detected in relation to the luciferase
FIGURE 2 | MiR-935 modulates cell proliferation and cell cycle in human glioma cell lines. (A) The quantitative PCR (qPCR) analysis showed the relative expression of miR-935 in the human glioma cell line, *p < 0.05, when compared to normal human glioma HEB cell line. (B) The qPCR analysis showed that miR-935 mimics enhanced the miR-935 expression in U87 cells and the miR-935 inhibitor-depressed miR-935 in SHG44 cells. The cell counting kit8 (CCK8) assay showed that the miR-935 mimic (C) significantly decreased the U87 cell proliferation, and the miR-935 inhibitor (D) significantly increased the SHG44 cell proliferation; *p < 0.05 at indicated time points. (E) The representative Western blotting of proliferation-related biomarker in the miR-935 mimic- or the inhibitor-treated glioma cell lines. (F) The bar chart showed the expression of β-catenin, cyclin D1, c-myc, and PCNA protein in the miR-935 mimics or inhibitor and respective NC transfected cells; *p < 0.05 between indicated groups. Values are the mean ± SD normalized micro-RNA or protein expression or relative cell counting presented by the CCK8 assays. (G) MiR-935 mimics significantly increased the cell circle G0/G1 phase transition in U87 cells and decreased the S phase and the G2/M phase cell distribution. (H) MiR-935 inhibitor depressed the proportion of the G0/G1 phase cells in the SHG44 cell line. The percentage of cells in the S phase was increased; *p < 0.05 between the indicated groups in the unpaired Student’s t-test.
signal of FZD6 3’UTR mutant group (*p < 0.05, Figure 4B). By using the qRT-PCR and Western blotting analyses, our data showed that the miR-935 mimics decreased the mRNA and protein levels of FZD6 in U87 cells (*p < 0.05, when compared to NC, treated U87 cells; Figures 4C,E) and the miR-935 inhibitors increased the expression of FZD6 in SHG44 cells (*p < 0.05 when compared to NC-treated SHG44 cells; Figures 4D,E). Furthermore, the mRNA and protein levels of FZD6 were also suppressed in the miR-935 mimic treated tumor samples collected from the xenograft nude mice model (*p < 0.05 when compared to miR-NC-treated animals; Figures 4F–H). The linear correlation analysis showed that the levels of FZD6 negatively correlated with the levels of miR-935 (Figure 4I).

**MicroRNA-935 Inhibits Proliferation by Modulating FZD6 in the Cell Lines of Patients With GMB**

To avoid the limitation and bias of the established GB cell line model, we built up primary cell lines that were derived from patients with GB who underwent surgery at the Tiantan Hospital. When treated with miR-935 mimics, the expression of miR-935 was significantly enhanced. At the same time, a dramatic decrease of the mRNA, as well as the protein expression of FZD6, was observed (Figures 5A–C). In line with our previous results, a significant proliferation inhibition was observed from 24 to 72 h after treatment in the miR-935 treated groups when compared to the NC-treated group (Figure 5D); the proliferation-related proteins (PCNA and c-myc) were also found to be downregulated (Figure 5E). The data gathered from the primary GB cell lines followed the phenomenon observed in the commercially established GB cell lines, providing further support for our hypothesis.

**Clinical Associations of miR-935 With FZD6 Expression in Human Glioma**

To further confirm that the expression of FZD6 is regulated by miR-935, we explored the relationship between the expression levels in human glioma tissues. As shown in Figure 5, the expression of miR-935 was significantly downregulated in glioma tumor tissues, when compared with the matched peri-tumor normal tissues (*p < 0.05, n = 16; Figure 6A). An adverse result was observed in the mRNA expression of FZD6 in clinical samples, which was significantly overexpressed in glioma tumor tissues (*p < 0.05, when compared to peri-tumor normal tissues, where n = 16; Figure 6B). We then tested the protein expression of FZD6 with western blotting; unsurprisingly, we noticed that the expression of FZD6 was significantly higher in the glioma tumor when compared to paired peri-tumor tissues (*p < 0.05, when compared to peri-tumor normal tissues, Figure 6C,D). Moreover, we analyzed the expression of FZD6 in the mRNAseq_325 dataset from the CGGA online database and found that the expression of FZD6 was increased gradually and significantly when classified by the WHO grades II, III and IV (Figure 6E). The higher expression of FZD6 correlated to a much worse overall survival time in all grade gliomas (p < 0.0001; Figure 6F), especially grade III glioma (p = 0.0092, Figure 6G) and grade IV GBs (p = 0.00072, Figure 6H). The overall data provided further evidence for the fact that miR-935 has a negative regulatory effect on FZD6; hence, FZD6 can be used as a biomarker for predicting the malignancy and prognosis of tumors.
FIGURE 4 | FZD6 is a direct target of miR-935 and it is downregulated in the human glioma cells. (A) The wild-type (WT) or mutant 3′-UTR construct of FZD6 built for the dual-luciferase assay. (B) Luciferase activity of the WT (mimic + WT) or mutant (mimic + mut) 3′-UTR construct of FZD6 in U87 cells after the transfection with miR-935 mimic or the negative control (NC). The quantitative real-time PCR (qRT-PCR) (C,D) and the Western blotting (E) analysis show that mRNA and protein expression of FZD6 were decreased in the miR-935 mimic transfected U87 cells and were promoted in the miR-935 inhibitor-treated SHG44 cells. (F) The qRT-PCR analysis compares the expression of FZD6 between the miR-935 mimic transfected tumors and the control isolated from the xenograft nude mice model. (G,H) The analysis of Western blotting was used to compare the expression of FZD6 and of proliferation-related biomarkers between the miR-935 mimic transfected tumors and the control-treated tumors from the xenograft nude mice model. (I) Negative correlation expression of miR-935 and FZD6 mRNA was generated by the Spearman’s rank correlation analysis. *p < 0.05 from the indicated groups in the unpaired Student’s t-test was used in the two groups, and a one-way ANOVA, followed by the Bonferroni test, was used to analyze the comparison of multiple groups.

Restoration of FZD6 Abolished the Effects of miR-935 on Cell Proliferation and Cell Cycle

To determine whether miR-935 suppresses the proliferation of human glioma cells or modulates the distribution of cell cycle in an FZD6-dependent manner, we performed rescue experiments by transfecting an overexpressing plasmid of FZD6 into U87 cells treated with miR-935 mimics. We first tested the transfection efficiency of the overexpression of FZD6, the FZD6 mRNA and protein expressions in the overexpression group (OE) were much higher when compared to the vector-treated (vector) and NC groups (*p < 0.05, Figure 7A). When FZD6 was overexpressed and transfected with the miR-935 mimics simultaneously, the higher expression of FZD6 was counteracted
by the miR-935 mimic treatment (Figure 7B). We also found that the cell proliferation of U87 cells was enhanced by the overexpression of FZD6 (OE + NC) at 48 and 72 h after treatment (*p < 0.05, when compared to the blank control group, Vector + NC, Figure 7C). Also, the suppression of cell proliferation in the miR-935 mimic-treated group (Vector + mimic) was counteracted by the overexpression of FZD6 (OE + mimic) (*p < 0.05 at 48 and 72 h, p > 0.05, when compared with Vector + NC, Figure 7C). We observed a similar phenomenon when assessed the proliferation-related biomarkers, such as β-catenin, cyclin-D1, c-myc, and PCNA. The overexpression of these biomarkers in the FZD overexpressed group was canceled by the miR-935 mimic transfection (Figure 7B). In the analysis of flow cytometry, the miR-935 enhancement remodulated the phase distribution shift induced by the overexpression of FZD in the G0/G1 phase and the S phase but not in the G2/M phase (*p < 0.05, when compared with the OE + mimic group than with the OE + NC group, Figures 7D,E). Taken together, these results indicated that the miR-935 mimic suppresses cell proliferation and regulates cell cycle distribution by targeting FZD6.

DISCUSSION

Glioblastoma is the most common malignant primary brain tumor that is featured with proliferative ability, leading to poor prognosis. Although multiple treatments were proved to be effective in glioma cell proliferation inhibition (24), the highly infiltrative properties result in a limited outcome of surgery and radiology therapies, within the remaining median survival time of only 15 months. The malignant behavior is caused by multi-step and multi-factor properties; however, the pathological mechanism is still unclear. The molecular mechanisms underlying the GB tumorigenesis may be able to reveal the potential targets to develop novel therapeutic approaches.

Previous studies have shown that miRNAs function as tumor suppressors or as oncogenes by regulating the gene expressions and signaling pathways. Increasing evidence revealed the effect of miRNAs on the tumor behavior and may play a critical prognostic biomarker in human GBs (19, 20, 25, 26). MiR-935 is a novel microRNA and has been found to regulate different types of human cancer pathologies. The overexpression of miR-935 was reported to promote cell proliferation, migration, cell invasion in clear cell renal carcinoma, in lung cancer, and in liver cancer (14–17, 27, 28). Meanwhile, the expression of miR-935 was found to be reduced in non-small-cell lung cancer and related to a poor outcome (29). These contradictory phenomena indicate that miR-935 may play different roles in different tumor types or subtypes. In this case, the possible regulatory role of miR-935 in GB remains to be explored. By analyzing the clinical genotyping
database, we found and further confirmed in our clinical samples that the expression level of miR-935 was significantly lower in GB tissues than that of adjacent normal tissues, and the lower expression of miR-935 was correlated to a poor overall survival probability. The functional analysis revealed that the abnormal expression of miR-935 was a remarkable negative correlation...
Zhang et al. Prognostic microRNA Biomarker in GB

FIGURE 7 | The rescue experiments of cell proliferation and cell cycle distribution. (A) The mRNA and protein expression of FZD6 in U87 cells modulated by the overexpression of FZD6 (OE) and control vectors (Vector). (B) The protein expression in U87 cells of FZD6 and proliferation-related biomarkers in the miR-935 mimics together with or without the overexpression of FZD6. (C) The cell proliferation was analyzed by the CCK8 assay, and the proliferated depression induced by miR-935 (open square, Vector + mimic) was alleviated by the co-overexpression of FZD6 (closed square, OE + mimic). While the overexpression of FZD6 enhanced the proliferation of U87 cells (closed circle, OE + NC). (D,E) The effect on the cell circle distribution of the miR-935 mimic treatment, together with or without FZD6 overexpression; *p < 0.05 at indicated time points or between the indicated groups, the one-way ANOVA followed by the Bonferroni test.

with the cell proliferation by affecting the percentage arrested in different phases of cell circles of GB cells both in vitro and in vivo.

FZD6 is a member of the “frizzled” gene family; this family encoded proteins that featured with a seven-transmembrane domain receptor, in which the N-terminal extracellular region was encoded by a cysteine-rich domain (30). As a minority of family members, FZD6 function as a negative regulator of the canonical Wnt/β-catenin signaling cascade (31, 32). FZD6 was reported to be upregulated and to promote cancer cell growth and metastasis in some cancer types, such as colorectal, pancreatic, or esophageal cancers; it is also related to poor overall survival (33–36). In the study of Cheng et al., FZD6, as an inhibitor of the Wnt signaling pathway, had a broad crosstalk with miRNAs, and the inhibition of FZD6 attenuates tumorigenic behaviors of GB in vitro and in vivo (37). By using the luciferase reporter assay, our data verified that miR-935 could directly bind to the 3’-UTR of FZD6 mRNA and suppresses the expression of FZD6. Furthermore, we carried out the recovery experiment and found that the overexpression of FZD6 fully reversed the inhibitory effect of miR-935 for cell proliferation, while its effect on cell cycle distribution was partially reversed. Taken together, our study showed that miR-935 directly targeted the gene of FZD6 to inhibit the malignant growth of human glioma. Based on these data, the miR-935/FZD6 axis may be a potential therapeutic target for future glioma or patients with GMB.

The data created by the present studies suggested that the miR-935/FZD6 axis plays a significant role in GB pathiology; however, the limitations of this study should be noticed. First, patient-derived cells from the PDX model will provide strong evidence for further understanding of this phenomenon and should be on top priority for studies in future. In addition, one of the major resources of our prognostic analysis was based on the CGGA database, for which the majority of the population was northern-east Asians. Although we observed that a strong overall trend with a higher expression of FZD6 correlated to a higher WHO grading and poorer prognosis in multiple datasets, the bioinformative analysis showed variations between datasets; because of the bias of patient recruitment or limited case numbers, a normalized analysis in bigger population and less bias may add much more confidence to the present studies.

In conclusion, this study showed that miR-935 was downregulated in human glioma and correlated to a poor prognostic outcome by directly regulating FZD6 in vitro or in vivo. The overexpression of miR-935 might provide a new
therapeutic strategy for the human glioma treatment; however, further study on the participation and the effect of the Wnt signaling pathway in the miR-935/FZD6 axis is warranted.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are openly available in Gene Expression Omnibus database (GEO, https://www.ncbi.nlm.nih.gov/geo/), dataset GSE25631; Chinese Glioma Genome Atlas (CGGA, http://www.cgga.org.cn/), dataset microRNA_array_198 and mRNAseq_395; TargetScan (http://www.targetscan.org/vert_72/).

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Beijing Tiantan hospital of Capital Medical University ethics committee (KY 2018-052-01). The patients/participants provided their written informed consent to participate in this study. The animal study was approved by Capital Medical University ethics committee.

REFERENCES
1. Batash R, Asna N, Schaffer P, Francis N, Schaffer M. Glioblastoma, diagnosis and treatment; recent literature review. Curr Med Chem. (2017) 24:3002–9. doi: 10.2174/0929867324666170516123206

2. Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P, Mampre D, Jacks on R. Glioblastoma , diagnosis and treatment; recent literature review. Curr Med Chem. (2017) 24:3002–9. doi: 10.2174/0929867324666170516123206

3. Aliferis C, Trafalis DT. Glioblastoma: pathogenesis and treatment. Pharmacol Ther. (2015) 152:63–82. doi: 10.1016/j.pharmthera.2015.05.005

4. Aliferis C, Trafalis DT. Glioblastoma: pathogenesis and treatment. Pharmacol Ther. (2015) 152:63–82. doi: 10.1016/j.pharmthera.2015.05.005

5. Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. (2015) 35:3–11. doi: 10.1055/s-0034-1397344

6. Agarwal R, Garg A, Bency Malgulwar P, Sharma V, Sarkar C, Kulshreshtha R. p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment. Int J Cancer. (2018) 142:1817–28. doi: 10.1002/ijc.31209

7. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. (2017) 16:203–22. doi: 10.1038/nrd.2016.246

8. Zhang G, Chen L, Khan AA, Li B, Gu B, Lin F, et al. miRNA-524–5p directly targets Jagged-1 and Hes-1 in glioma. Carcinogenesis. (2012) 33:2276–82. doi: 10.1093/carcin/bgs126

9. Chen L, Zhang W, Yan W, Han L, Zhang K, Shi Z, et al. The putative tumor suppressor miR-524–5p directly targets Jagged-1 and Hes-1 in glioma. Carcinogenesis. (2012) 33:2276–82. doi: 10.1093/carcin/bgs126

10. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, et al. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-oncology. (2012) 14:712–9. doi: 10.1093/neuonc/noq089

11. Dong F, Eibach M, Bartsch JW, Dolga AM, Schlomann U, Conrad C, et al. The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells. Neuro Oncol. (2015) 17:1474–85. doi: 10.1093/neuonc/nov042

12. Huang K, Liu X, Li Y, Wang Q, et al. Genome-wide CRISPR-Cas9 screening identifies NF-KB/E2F6 responsible for EGFRvIII-associated temozolomide resistance in glioblastoma. Adv Sci. (2019) 6:1900782. doi: 10.1002/advs.201900782

13. Zhang G, Chen L, Khan AA, Li B, Kamal MM, Singh SK, et al. MiR-21-1p axis delineates glioblastoma subtypes with prognostic impact. J Neurosci. (2015) 35:15097–112. doi: 10.1523/JNEUROSCI.1265-15.2015

14. Liu F, Chen Y, Chen B, Liu C, Xing J. MiR-935 promotes clear cell renal cell carcinoma migration and invasion by targeting 1RE2B. Cancer Manag Res. (2011) 10:359–900. doi: 10.2147/CMAR.S232380

15. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, et al. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-oncology. (2012) 14:712–9. doi: 10.1093/neuonc/noq089

16. Wang C, Feng Z, Jiang K, Zuo X. Upregulation of MicroRNA-935 promotes the malignant behaviors of pancreatic carcinoma Panc-1 cells via targeting inositol polyphosphate 4-phosphatase type I gene (INPP4A). Oncol Res. (2017) 25:559–69. doi: 10.3727/096504016X14759554689565

17. Liu X, Li Q, Xin R, Kan Q. MiR-935 acts as a prognostic marker in breast cancer. Oncol Rep. (2018) 26:1439–46. doi: 10.3727/096504018X15189093975640

18. Liu X, Li Q, Zhao X, Cui B, Zhang L, Wang Q. MicroRNA-935 inhibits proliferation and invasion of osteosarcoma cells by directly targeting High mobility group box 1. Oncol Res. (2018) 26:1439–46. doi: 10.3727/096504018X15189093975640

19. Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. (2015) 35:3–11. doi: 10.1055/s-0034-1397344

20. Choudhary A, Lambert KC, Shams converted miR-210 to its proangiogenic isoform in glioblastoma. Cancer Res. (2012) 71:1507–16. doi: 10.1158/0008-5472.CAN-11-1270

21. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, et al. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-oncology. (2012) 14:712–9. doi: 10.1093/neuonc/noq089

22. Dong F, Eibach M, Bartsch JW, Dolga AM, Schlomann U, Conrad C, et al. The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells. Neuro Oncol. (2015) 17:1474–85. doi: 10.1093/neuonc/nov042

23. Huang K, Liu X, Li Y, Wang Q, Zhou J, Wang Y, et al. Genome-wide CRISPR-Cas9 screening identifies NF-KB/E2F6 responsible for EGFRvIII-associated temozolomide resistance in glioblastoma. Adv Sci. (2019) 6:1900782. doi: 10.1002/advs.201900782

24. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, et al. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-oncology. (2012) 14:712–9. doi: 10.1093/neuonc/noq089

25. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, et al. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-oncology. (2012) 14:712–9. doi: 10.1093/neuonc/noq089

26. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, et al. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-oncology. (2012) 14:712–9. doi: 10.1093/neuonc/noq089

FUNDING
This study was supported by the National Natural Science Foundation of China (No. 81701085 and U1804199), the Capital’s Funds for Health Improvement and Research (No. CFH 2018-1-1071), and the Henan Key Laboratory of Neural Regeneration and Repairment (No. HNSJXF-2018-001).

AUTHOR CONTRIBUTIONS
SL and WJ did the project design and manuscript writing. DZ, XW, and SM performed the animal and cellular experiments. CZ and XG archived the bio-informative analysis. PL, BM, WZ, and JP put much effort into the animal farewell and breeding. All authors contributed to the article and approved the submitted version.

AUTHOR CONTRIBUTIONS
SL and WJ did the project design and manuscript writing. DZ, XW, and SM performed the animal and cellular experiments. CZ and XG archived the bio-informative analysis. PL, BM, WZ, and JP put much effort into the animal farewell and breeding. All authors contributed to the article and approved the submitted version.
Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA, et al. Gliomas display a microRNA expression profile reminiscent of neural precursor cells. *Neuro-oncology.* (2010) 12:422–33. doi: 10.1093/neuonc/nop061

Jiang L, Mao P, Song L, Wu J, Huang J, Lin C, et al. miR-182 as a prognostic marker for glioma progression and patient survival. *Am J Pathol.* (2010) 177:29–38. doi: 10.2353/ajpath.2010.090812

Yang M, Cui G, Ding M, Yang W, Liu Y, Dai D, et al. miR-935 promotes gastric cancer cell proliferation by targeting SOX7. *Biomed Pharmacother.* (2016) 79:153–8. doi: 10.1016/j.biopha.2016.01.011

Zhang L, Zeng D, Chen Y, Li N, Lv Y, Li Y, et al. miR-937 contributes to the lung cancer cell proliferation by targeting INPP4B. *Life Sci.* (2016) 155:110–5. doi: 10.1016/j.lfs.2016.05.014

Wang C, Li S, Xu J, Niu W, Li S. microRNA-935 is reduced in non-small cell lung cancer tissue, is linked to poor outcome, and acts on signal transduction mediator E2F7 and the AKT pathway. *Br J Biomed Sci.* (2019) 76:17–23. doi: 10.1080/09674845.2018.1520066

Kozielewicz P, Turku A, Bowin CF, Petersen J, Valnohova J, Canizal MCA, et al. Structural insight into small molecule action on Frizzleds. *Nat Commun.* (2020) 11:414. doi: 10.1038/s41467-019-14149-3

Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. *Nat Rev Cancer.* (2013) 13:11–26. doi: 10.1038/nrc3419

Kahn M. Can we safely target the WNT pathway? *Nat Rev Drug Discov.* (2014) 13:513–32. doi: 10.1038/nrd4233

Gororno-Etxebarria I, Aguirre UA-O, Sanchez S, Gonzalez NAO, Escobar A, Zabalza I, et al. Wnt-11 as a potential prognostic biomarker and therapeutic target in colorectal cancer. *Cancers.* (2019) 11:908. doi: 10.3390/cancers11070908

Yuan Y, Wang Q, Ma SL, Xu LQ, Liu MY, Han B, et al. IncRNA PCAT-1 interacting with FZD6 contributes to the malignancy of acute myeloid leukemia cells through activating Wnt/beta-catenin signaling pathway. *Am J Transl Res.* (2019) 11:7104–14. doi: 10.1002/HON.2651

Zhang J, Wang JL, Zhang CY, Ma YF, Zhao R, Wang YYA. The prognostic role of FZD6 in esophageal squamous cell carcinoma patients. *Clin Transl Oncol.* (2020) 22:1172–9. doi: 10.1007/s12094-019-02243-3

Huang T, Alvarez AA, Panegi RP, Horbinski CM, Lu S, Kim SH, et al. A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. *Nat Commun.* (2016) 7:12885. doi: 10.1038/ncomms12885

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Ma, Zhang, Li, Mao, Guan, Zhou, Peng, Wang, Li and Jia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.